Amgen has completed the acquisition of Teneobio, a biotechnology company that develops a new class of biologics called Human Heavy-Chain Antibodies. Teneobio owns proprietary bispecific and multispecific antibody technologies, which will enable Amgen to significantly accelerate the development of new molecules to treat a wide range of diseases. Amgen has paid $900 million upfront and could pay up to $1.6 billion in contingent payments.